The prognostic effect of statin use on urologic cancers: An updated meta-analysis of 35 observational studies

Medicine (United States)

Volumn 94, Issue 36, 2015, Pages

  Luo, You ^a   She, Dong Li ^a   Xiong, Hu ^a   Fu, Sheng Jun ^a   Yang, Li ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BIOCHEMICAL RECURRENCE; BLADDER CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CANCER THERAPY; CLINICAL EVALUATION; DRUG EFFECT; EMBASE; HAZARD RATIO; HUMAN; KIDNEY CARCINOMA; MEDICAL INFORMATION; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY CONTROL; RADIOSENSITIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; TUMOR GROWTH; WEB OF SCIENCE; CARCINOMA, RENAL CELL; DISEASE COURSE; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL; URINARY BLADDER NEOPLASMS;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84941640805     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001523     Document Type: Article

References (59)

1. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008;44:2122-2132.
2. Allott EH, Howard LE, Cooperberg MR, et al. Serum lipid profile and risk of prostate cancer recurrence: results from the SEARCH Database. Cancer Epidemiol Biomarkers Prev. 2014;23:2349-2356.
3. Cardwell CR, Hicks BM, Hughes C, et al. Statin use after diagnosis of breast cancer and survival. Epidemiology. 2015;26:68-78.
4. Hamilton RJ, Banez LL, Aronson WJ, et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer. 2010;116:3389-3398.
5. Ritch CR, Hruby G, Badani KK, et al. Effect of statin use on biochemical outcome following radical prostatectomy. BJU Int. 2011;108:E211-E216.
6. Luo Y, She D, Hu X, et al. Statin use in the treatment of urologic cancer patients: a systematic review and meta-analysis. Prospero. 2015:CRD42015020171http://www.crd.york.ac.uk/PROSPERO-REBRANDING/display-record.asp?ID1/4CRD42015020171, access date: May 2015.
7. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8: 16.
8. Park HS, Schoenfeld JD, Mailhot RB, et al. Statins and prostate cancer recurrence following radical prostatectomy or radiotherapy: a systematic review and meta-analysis. Ann Oncol. 2013;24:1427-1434.
9. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2008. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Access date: May 2015.
10. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011.]. http://www.cochrane-handbook.org. Access date: May 2015.
11. Egger M, Davey SG, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634.
12. Berglund RK, Savage CJ, Vora KC, et al. An analysis of the effect of statin use on the efficacy of bacillus Calmette-Guerin treatment for transitional cell carcinoma of the bladder. J Urol. 2008;180:1297-1300.
13. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. BJU Int. 2013;112:E4-E12.
14. Da Silva RD, Xylinas E, Kluth L, et al. Impact of statin use on oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2013;190:1427.
15. Choi SK, Min GE, Jeon SH, et al. Effects of statins on the prognosis of local and locally advanced renal cell carcinoma following nephrectomy. Mol Clin Oncol. 2013;1:365-368.
16. Hamilton RJ, Morilla D, Cabrera F, et al. The association between statin medication and progression after surgery for localized renal cell carcinoma. J Urol. 2014;191:914-919.
17. Kaffenberger SD, Lin-Tsai O, Stratton KL, et al. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Urol Oncol. 2015;33:21e11-21e7.
18. Viers BR, Houston Thompson R, Psutka SP, et al. The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. Urol Oncol Semin Orig Investig. 2015;33:388e11-18. doi:10.1016/j.urolonc.2015.01.009.
19. Caon J, Paquette M, Hamm J, et al. Does statin or ASA affect survival when prostate cancer is treated with external beam radiation therapy? Prostate Cancer. 2014;2014:184297.
20. Chao C, Jacobsen SJ, Xu L, et al. Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy. BJU Int. 2013;111:954-962.
21. Chao C, Williams SG, Xu L, et al. Statin therapy is not associated with prostate cancer recurrence among patients who underwent radiation therapy. Cancer Lett. 2013;335:214-218.
22. Cuaron J, Pei X, Cohen GN, et al. Statin use not associated with improved outcomes in patients treated with brachytherapy for prostate cancer. Brachytherapy. 2015;14:179-184.
23. Geybels MS, Wright JL, Holt SK, et al. Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate. 2013;73:1214-1222.
24. Grytli HH, Fagerland MW, Fossa SD, et al. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65:635-641.
25. Gutt R, Tonlaar N, Kunnavakkam R, et al. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol. 2010;28:2653-2659.
26. Ishak-Howard MB, Okoth LA, Cooney KA. Statin use and the risk of recurrence after radical prostatectomy in a cohort of men with inherited and/or early-onset forms of prostate cancer. Urology. 2014;83:1356-1361.
27. Katz MS, Carroll PR, Cowan JE, et al. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010;106:627-632.
28. Kollmeier MA, Katz MS, Mak K, et al. Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2011;79:713-718.
29. Kontraros M, Varkarakis I, Ntoumas K, et al. Pathological characteristics, biochemical recurrence and functional outcome in radical prostatectomy patients on statin therapy. Urol Int. 2013;90:263-269.
30. Ku JH, Jeong CW, Park YH, et al. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis. 2011;14:63-68.
31. Misrai V, Do C, Lhez J-MM, et al. Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy? Prog Urol. 2012;22:273-278.
32. Moyad MA, Merrick GS, Butler WM, et al. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs. 2006;26:298-303.
33. Oh DS, Koontz B, Freedland SJ, et al. Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. World J Urol. 2014;33:93-97.
34. Rieken M, Kluth LA, Xylinas E, et al. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. Prostate Cancer Prostatic Dis. 2013;16:367-371.
35. Song C, Park S, Park J, et al. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate. 2015;75:211-217.
36. Soto DE, Daignault S, Sandler HM, et al. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology. 2009;73:158-162.
37. Yu O, Eberg M, Benayoun S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32:5-11.
38. Zaorsky NG, Buyyounouski MK, Li T, et al. Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:e13-e17.
39. Mass AY, Agalliu I, Laze J, et al. Preoperative statin therapy is not associated with biochemical recurrence after radical prostatectomy: our experience and meta-analysis. J Urol. 2012;188:786-791.
40. Krane LS, Kaul SA, Stricker HJ, et al. Men presenting for radical prostatectomy on preoperative statin therapy have reduced serum prostate specific antigen. J Urol. 2010;183:118-125.
41. Mondul AM, Han M, Humphreys EB, et al. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol. 2011;185:1268-1273.
42. Choe KS, Cowan JE, Chan JM, et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30:3540-3544.
43. Niraula S, Pond G, de Wit R, et al. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J. 2013;7:E74-81.
44. Cattarino S, Seisen T, Drouin SJ, et al. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study. Can J Urol. 2015;22:7703-7708.
45. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004-1010.
46. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994-1998.
47. Hindler K, Cleeland CS, Rivera E, et al. The role of statins in cancer therapy. Oncologist. 2006;11:306-315.
48. Sun Y, Sukumaran P, Varma A, et al. Cholesterol-induced activation of TRPM7 regulate cell proliferation, migration, and viability of human prostate cells. Biochim Biophys Acta. 2014;1843:1839-1850.
49. Banez LL, Klink JC, Jayachandran J, et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010;19:722-728.
50. Mantovani A, Mantovani A, Allavena P, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
51. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-867.
52. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211-217.
53. Baniyash M, Sade-Feldman M, Kanterman J. Chronic inflammation and cancer: suppressing the suppressors. Cancer Immunol Immunother. 2014;63:11-20.
54. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. vol. 355. United States: 2006. doi:10.1056/NEJMc062714.
55. Orsola A, Cecchini L, Bellmunt J. Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007; 356: 1276.
56. Shi Y, Fung KZ, Freedland SJ, et al. Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result. Urology. 2014;84:1058-1065.
57. He Z, Mangala LS, Theriot CA, et al. Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells. J Radiat Res. 2012;53:225-233.
58. Bruckert E, Ferrieres J. Evidence supporting primary prevention of cardiovascular diseases with statins: gaps between updated clinical results and actual practice. Arch Cardiovasc Dis. 2014;107:188-200.
59. Hayden A, Douglas J, Sommerlad M, et al. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol Oncol. 2014;32:806-814.